PMDI (Psychemedics) YoY EBITDA Growth: 171.53% (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PMDI Psychemedics Corp PMDI
58 GF Score
Price $2.49
View Full Analysis

What is Psychemedics YoY EBITDA Growth?

Psychemedics PMDI +13.18% 58 YoY EBITDA Growth is 171.53% as of Dec. 2024. GuruFocus rates PMDI with a GF Score™ of 58/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Psychemedics's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 171.53%.

Psychemedics's EBITDA per Share for the three months ended in Dec. 2024 was $0.10.

Psychemedics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Psychemedics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Psychemedics YoY EBITDA Growth Chart

Psychemedics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -141.31 259.05 -43.53 -133.00 125.19

Psychemedics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -290.28 -109.09 -181.63 67.12 171.53
PMDI
58GF Score
Psychemedics Corp PMDI
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Psychemedics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Psychemedics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(0.033--0.131)/ | -0.131 |
=125.19 %

Psychemedics's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(0.098--0.137)/ | -0.137 |
=171.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 171.53% mean?
Psychemedics (PMDI) has a YoY EBITDA Growth of 171.53% as of Dec. 2024. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Psychemedics and its competitors.
Is Psychemedics' YoY EBITDA Growth too high?
Psychemedics' current YoY EBITDA Growth is 171.53%. Overall, Psychemedics has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Psychemedics' YoY EBITDA Growth compare to MBAI and MYNZ?
Psychemedics' YoY EBITDA Growth of 171.53% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Diagnostics & Research company?
A good YoY EBITDA Growth depends on the Medical Diagnostics & Research industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Psychemedics and its competitors. Psychemedics's current YoY EBITDA Growth is 171.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psychemedics stock overvalued right now?
Psychemedics (PMDI) has a current YoY EBITDA Growth of 171.53%. The current YoY EBITDA Growth is 171.53%. Psychemedics' overall GF Score™ is 58/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Psychemedics (PMDI), the current YoY EBITDA Growth is 171.53% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Psychemedics Business Description

Address 5220 Spring Valley Road, Suite 230, Dallas, TX, USA, 75254
Psychemedics Corp provides testing services for the detection of drug abuse and other health markers through the analysis of hair samples. The company generates revenue mainly from providing drug and alcohol testing services for its customers for an agreed-upon fee per unit tested. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in it without destroying the drugs. Geographically, the majority of its revenue comes from the United States, and also has a presence in other markets.
58GF Score

Get the complete analysis for PMDI

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.49
Price